PANEL DISCUSSION: Is clinical trial exclusion criteria too stringent?

  • How is the industry approaching diversity and what should the primary focus be?
  • Increasing accessibility to trials whilst simultaneously maintaining an appropriate level of patient safety
  • Assessing the link between restrictive eligibility criteria and rates of serious adverse events to make informed decisions on expanding exclusion conditions
  • Alternative solutions to improve patient numbers amidst pressures to hit recruitment milestones
  • How have increased pressures of patient recruitment lead to the questioning of traditional enrollment methods?

Chair: Cathy Scharf, Patient Advocate, Patient Advocates of the East Bay